Dupixent (dupilumab)

Manufacturer:
Sanofi | Regeneron
Route of Administration: 
Subcutaneous
Site of Care:
Outpatient
Website: 
  • Manufacturer Website
phone: 
1-844-387-4936

Approved Indication:

    • treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
    • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma
    • add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps
    • treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kilograms, with eosinophilic esophagitis
    • treatment of adult patients with prurigo nodularis
    • add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype
    • treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment

Conditions:

  • Asthma
  • Atopic Dermatitis
  • Chronic Obstructive Pulmonary Disease
  • Chronic Rhinosinusitis with Nasal Polyp
  • Chronic Spontaneous Urticaria
  • Eosinophilic Esophagitis
  • Prurigo Nodularis

Therapeutic Area:

  • Dermatology
  • Gastroenterology
  • Rheumatology